Search
forLearn
5 / 801 resultslearn octapeptide-2
learn acetyl tetrapeptide-3
learn ACETYL TETRAPEPTIDE-2
learn copper tripeptide-1
Research
5 / 1000+ resultsresearch Case Report: Secondary syphilitic alopecia following non-penetrative sexual contact: a case of initial misdiagnosis
A 26-year-old male was initially misdiagnosed with alopecia areata but was later found to have secondary syphilitic alopecia following non-penetrative sexual contact. The patient had moth-eaten patchy alopecia and a small erythematous papule on the penile frenulum. Serological tests confirmed syphilis, with an RPR titer of 1:32 and a positive TPPA. He was treated with benzathine penicillin G, 2.4 million units intramuscularly weekly for 3 weeks, resulting in complete hair regrowth within 3 months without scarring.
research Alopecia syphilitica diffusa
Treatment with benzylpenicillin and prednisolone cured the patient's syphilis and hair loss.
research A rash diagnosis
The man's rash, hair loss, and vision issues were due to syphilis, not CMV.
research Alopecia Areata: a Comprehensive Review of Pathogenesis and Management
New treatments for Alopecia Areata show promise but need to be more effective and affordable.
research The Diagnosis and Treatment of Hair and Scalp Diseases
Hair loss requires customized treatments based on its various causes and types.
Community Join
5 / 1000+ resultscommunity mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
community Approve PP405 quickly you coward
Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community A warning to anyone considering 3rd party sourcing PP405 or its analogs
Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.
community Full extent of pp405 effectiveness
The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.